Clinical Trial Update: Risk Adapted Therapy Optimization for Patients With Relapsed or Refractory Aggressive Non-Hodgkin-Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a risk-adapted therapy optimization approach for patients with relapsed or refractory aggressive non-Hodgkin lymphoma, span…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Snippet

Sponsor: University of Magdeburg | Conditions: Non-Hodgkin's Lymphoma | Phase 1, Phase 2 | Status: UNKNOWN